On 12 January Glancy Binkow & Goldberg LLP reminds investors of Alcobra, Ltd. (NASDAQ:ADHD) that purchasers of Alcobra securities between March 28, 2014 and November 14, 2014, inclusive (the “Class Period”), have until January 19, 2015, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the Southern District of New York. On Friday shares of Alcobra Ltd. (NASDAQ:ADHD) closed at $6.98.
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders on 6 January announced that the Superior Court of the State of California, County of Orange (the “Court”), has issued a tentative ruling and proposed statement of decision (the “Proposed Statement of Decision”) in the matter of the People of the State of California and Relator Michael Strathmann (“Plaintiff”) vs. Acacia Research Corporation, CombiMatrix Corporation and Amit Kumar (“Defendants”). CombiMatrix Corporation (NASDAQ:CBMX) in last trading activity moved up 6.52% to close at $1.47. Company weekly performance is -6.96% while its quarterly performance stands at -0.68%. CombiMatrix Corporation (NASDAQ:CBMX) is -59.73% away from its 52 week high.
Hyperdynamics Corporation (NYSE: HDY) announced that it received notice on January 9, 2015 from the New York Stock Exchange (NYSE) that it did not satisfy the NYSE’s continued listing criteria. The NYSE noted that a Company will be considered “below criteria” if the average closing price of its security is less than $1.00 per share over a consecutive 30 trading-day period. On last trading day Hyperdynamics Corporation (NYSE:HDY) remains unchanged to close at $0.78. Its volatility for the week is 11.11% while volatility for the month is 8.31%. HDY’s EPS growth for past 5 years was 7.60%. Hyperdynamics Corporation (NYSE:HDY) monthly performance is -16.13%.
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) on 6 January announced that it has concluded consultations with U.S. and European health authorities regarding the design of a randomized, dose-ranging trial to evaluate three starting doses of Iclusig® (ponatinib) in patients with refractory, chronic-phase chronic myeloid leukemia (CP-CML). The trial is expected to inform the optimal use of Iclusig in these patients and will begin by mid-2015. Approximately 450 patients will be enrolled at clinical sites around the world. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) has 1.30% insider ownership while its institutional ownership stands at 67.00%. In last trading activity company’s stock closed at $6.24.
Mettler-Toledo International Inc. (NYSE:MTD) announced that Dr. Martin D. Madaus will be retiring as a director of the Board, effective May 7, 2015, to fully devote time to his new role as Chairman and Chief Executive Officer of Ortho-Clinical Diagnostics. On last trading day Mettler-Toledo International Inc. (NYSE:MTD) moved up 1.01% to close at $292.00. Its volatility for the week is 2.56% while volatility for the month is 2.06%. MTD’s sales growth for past 5 years was 3.80% and its EPS growth for past 5 years was 11.50%. Mettler-Toledo International Inc. (NYSE:MTD) monthly performance is 4.60%.